New and Old Therapeutic Options for Crohn’s Disease
Submission Deadline: May 1, 2019 (Open) Submit Now
Tony C. K. Tham, MD, MB BCh BAO, MSc, FRCP, FRCPI
Consultant Gastroenterologist and President -elect, Irish Society of Gastroenterology
Division of Gastroenterology, Ulster Hospital, Dundonald, Belfast, United Kingdom
E-mails: [email protected]
Research Interests: Gastrointestinal haemorrhage; inflammatory bowel disease; endoscopic mucosal resection; pancreatobiliary disease; ERCP; dysplastic Barretts; gastrointestinal consequences of pelvic radiotherapy
About This Topic
There are currently four biologic therapies available for Crohn’s disease and many new therapeutic options such as small molecules in the development pipeline. There are also currently other well established drugs such as thiopurines, methotrexate, budesonide and steroids for the treatment of Crohn’s. In addition, other therapeutic options include surgery, endoscopic therapy and dietary intervention. This special issue seeks submissions that address the role of these treatment options for the management of Crohn’s, how these options can be used in treatment pathways, how these therapies can be combined to best effect, and how to select the right patient for the right intervention. The submissions can be in the form of review articles, opinions or original research. We would like to invite you to submit your work for consideration of publication in this special issue.
Title: Managing Fatty Liver Disease in the Inflammatory Bowel Disease Patient
Authors: Ordway S, Sadowski B, Tritsch A, Singla M
Affiliations: Uniformed Services University of Health Sciences, Bethesda, MD; Walter Reed National Military Medical Center, Bethesda, MD
Title: The management of perianal fistulas in Crohn's diaseas: systematic review
Authors: Roberta Tutino, Claudia Carolla, Saverio Barbera, Gianfranco Cocorullo, Gaspare Gulotta
Affiliations: Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy
Title: Advanced endoscopic therapies in Crohn's disease
Authors: Wong A, Lee SD
Affiliation: Department of Medicine, Division of Gastroenterology, University of Washington Medical Center, Seattle, WA, USA.
Crohn’s disease is a chronic progressive transmural disease that overtime leads to complications such as strictures, fistulas, and abscesses. While the majority of patients present with non-penetrating disease at diagnosis, around 50-60% develop fibrostenotic disease over time. Endoscopy serves an important role in the diagnosis, management, and treatment of inflammatory bowel disease. It not only helps distinguish between Crohn’s disease and ulcerative colitis, but can also diagnose and manage mechanical adverse events. Endoscopic therapy, a less invasive alternative to surgical options, bridges the gap between medical and surgical treatments. Endoscopic tools include video capsule endoscopy, small bowel enteroscopy, endoscopic balloon dilation, as well as other more novel investigational therapies. This review will focus on using advanced endoscopic therapeutic techniques for the diagnosis and management of complications in Crohn’s disease.
Title: New and Old Therapeutic Options for Luminal Crohn's Disease - An Overview of Current Literature
Authors: Rachel Rutherford, Patrick B Allen
Affiliation: Department of Medicine and Gastroenterology, SE Trust, Belfast NI UK
Crohn's Disease (CD) is a chronic inflammatory, relapsing and remitting condition that leads to structural damage of the bowel wall. It can be located in any part of the gastrointestinal tract with associated extra-intestinal manifestations. It varies in severity having many complications resulting in significant morbidity. In the past decade medical management of CD has evolved rapidly and with ongoing research it continues to show promising novel therapies. In this article we aim to give an overview of current literature on old and new therapy options for luminal CD looking at data including their efficacy and safety. With new oral biologic therapies such as the Janus Kinase inhibitor and gut specific targeted therapies developing their place in this ever growing marketplace treatment options for physicians are going to become even more challenging.